Aleniglipron T2D data is limited to early-phase studies
The combination uses therapeutic but conservative doses of each component, and the synergistic effects actually allow for lower individual peptide amounts than if using them separately
Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations
Medical history and demographic information were self-reported at baseline
These powerful medications help effectively manage appetite and improve metabolic health, while Dr
Funding: This work was supported by grants from the Science and Technology Innovation 2030-Major Project of the Ministry of Science and Technology of China, the National Natural Science Foundation of Distinguished Young Scholars, the National Natural Science Foundation of China, the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, the Major Science and Technology Projects in Jiangsu Province, the Natural Science Foundation Outstanding Youth Fund of Jiangsu Province, the Fundamental Research Funds for the Central Universities, the Jiangsu Province High-Level Hospital Construction Funds of Zhongda Hospital, School of Medicine, Southeast University, and the Nanjing U35 Strong Foundation Program